Skip to search formSkip to main contentSkip to account menu

SB 207499

Known as: SB-207499 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2002
2002
Background. Recent advances in the understanding of immunomodulatory properties of phosphodiesterase 4 (PDE4) inhibitors… 
2000
2000
  • T. Torphy
  • 2000
  • Corpus ID: 30380859
This meeting underscored advances in the exploitation of cyclic nucleotide phosphodiesterases (PDEs) as drug targets. One… 
1999
1999
  • W. Brown
  • 1999
  • Corpus ID: 41061044
Ariflo (SB-207499) is a phosphodiesterase (PDE)4 inhibitor under development by SmithKline Beecham and in phase III and II… 
1997
1997
Phosphodiesterase type IV (PDE IV) inhibitors have wide ranging anti-inflammatory effects which have given rise to the concept… 
1995
1995
&The enzyme phosphodiesterase (PDE) IV is a target for several companies seeking to develop innovative agents with both anti…